ONCWF (Oncolytics Biotech) Short-Term Capital Lease Obligation : $0.19 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Oncolytics Biotech Short-Term Capital Lease Obligation?

Oncolytics Biotech's Short-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.19 Mil.

Oncolytics Biotech's quarterly Short-Term Capital Lease Obligation increased from Mar. 2024 ($0.13 Mil) to Jun. 2024 ($0.16 Mil) and increased from Jun. 2024 ($0.16 Mil) to Sep. 2024 ($0.19 Mil).

Oncolytics Biotech's annual Short-Term Capital Lease Obligation declined from Dec. 2021 ($0.23 Mil) to Dec. 2022 ($0.16 Mil) and declined from Dec. 2022 ($0.16 Mil) to Dec. 2023 ($0.10 Mil).

Oncolytics Biotech Short-Term Capital Lease Obligation Historical Data

The historical data trend for Oncolytics Biotech's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Short-Term Capital Lease Obligation Chart

Oncolytics Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.26

0.19

0.23

0.16

0.10

Oncolytics Biotech Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.14	0.10	0.13	0.16	0.19

Oncolytics Biotech Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Oncolytics Biotech Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncolytics Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (OTCPK:ONCWF) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ONCY:USA ONC:Canada

Address

322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5

Website

https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.